Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$43.76

0.525 (1.21%)

07:36
07/11/19
07/11
07:36
07/11/19
07:36

Biohaven Pharmaceutical's rimegepant featured in 16 presentations at AHS meeting

Biohaven Pharmaceutical will present 16 scientific presentations highlighting new efficacy and safety data for rimegepant from Biohaven's clinical development program at the American Headache Society Annual Scientific Meeting in Philadelphia, July 11-14. Biohaven will be presenting results from the rimegepant Zydis oral fast-dissolve tablet Phase 3 trial, new analyses across the three Phase 3 trials, results from the rimegepant long-term safety study, and new clinical pharmacology data. Rimegepant is an oral, single dose, selective and potent small molecule calcitonin gene-related peptide receptor antagonist in development for the acute treatment of migraine. Consistent with the two previous Phase 3 clinical trials for rimegepant oral tablet, Study 303 met its co-primary endpoints of pain freedom and freedom from the most bothersome symptom at two hours using a single dose. Importantly, patients treated with the rimegepant Zydis ODT formulation began to experience pain relief as early as 15 minutes, with numerical separation from placebo, and this difference was statistically significant at 60 minutes. Additionally, a significantly greater percentage of patients treated with rimegepant Zydis ODT returned to normal functioning by 60 minutes as compared to placebo. Sustained clinical benefit was observed through 48 hours after a single dose of rimegepant. The co-primary endpoints achieved in all three Phase 3 trials are consistent with regulatory guidance from the FDA for NDA submissions.

  • 09

    Sep

BHVN Biohaven Pharmaceutical
$43.76

0.525 (1.21%)

06/18/19
LEER
06/18/19
NO CHANGE
LEER
Outperform
Biohaven equity raise could be negotiation tactic, says SVB Leerink
SVB Leerink analyst Marc Goodman says that while the $300M equity raise announced last night by Biohaven Pharmaceutical will disappoint investors, the offering could be a negotiation tactic whereby management is showing potential buyers that it is serious about possibly going it alone. Biohaven shares in premarket trading are down 29%, or $16.62, to $40.74. The stock was around $50 in early April before Bloomberg reported that the company was in early stages of considering a sale or partnerships, and the news brought the stock up 20% to around $60, Goodman tells investors in a research note. Since then, the stock rose another 20% when Biohaven cancelled its scheduled attendance at a healthcare conference last week, adds the analyst. Goodman still likes the company's fundamentals and keeps an Outperform rating on the shares with a $67 price target.
06/18/19
ADAM
06/18/19
NO CHANGE
Target $89
ADAM
Buy
Biohaven downside over past few days a buying opportunity, says Canaccord
Canaccord analyst Sumant Kulkarni said he believes it would have been better if the narrative for Biohaven Pharmaceutical "could have somehow been different or perhaps controlled differently" after a "curious mix of events," but he sees the weakness of the last few days presenting a buying opportunity. The "curious" events began with a buyout rumor in April, the company pulling out of an investor conference last week, and then weakness yesterday that the company said it could not explain followed by a $300M stock offering, which he acknowledges could leave investors "shaken." However, Kulkarni sees several important catalysts over the next 6-9 months, including the potential approval of rimegepant for the acute treatment of migraine and Phase 3 data on migraine prevention. The analyst, who contends that the fundraising rationale "appears valid IF emotion is set aside," keeps a Buy rating and $89 price target on Biohaven shares.
06/25/19
ADAM
06/25/19
NO CHANGE
Target $84
ADAM
Buy
Biohaven Pharmaceutical weakness a buying opportunity, says Canaccord
Canaccord analyst Sumant Kulkarni hosted meetings with Biohaven Pharmaceuticals management and came away with a heightened confidence in his thesis. The analyst recommended buying the stock on the recent pullback ahead of the crucial migraine prevention data that is expected in Q4. Kulkarni reiterated his Buy rating and $84 price target on Biohaven Pharmaceuticals shares.
07/01/19
PIPR
07/01/19
NO CHANGE
PIPR
Overweight
Piper says concerns about rimegepant's filing status 'put to bed' by Biohaven
Piper Jaffray analyst Tyler Van Buren noted that Biohaven Pharmaceutical issued a press release about the first patient being enrolled in the Phase 2 trial of rimegepant for the treatment of refractory trigeminal neuralgia, calling "the more interesting disclosure" the company's confirmation of the filing of the rimegepant NDAs for the oral pill and ODT formulations. There had recently been some uncertainty among investors on the status of the rimegepant NDA filings, but he thinks those concerns "can now officially be put to bed." Van Buren, who keeps an Overweight rating Biohaven said he has a high level of confidence in the eventual launch of rimegepant.

TODAY'S FREE FLY STORIES

EGHT

8x8, Inc.

$25.38

-0.24 (-0.94%)

, FIVN

Five9

$50.13

2.13 (4.44%)

10:25
07/16/19
07/16
10:25
07/16/19
10:25
Conference/Events
Stephens communications analysts to hold an analyst/industry conference call »

Communications Analysts,…

EGHT

8x8, Inc.

$25.38

-0.24 (-0.94%)

FIVN

Five9

$50.13

2.13 (4.44%)

LOGM

LogMeln

$76.20

-0.37 (-0.48%)

RNG

RingCentral

$124.44

1.13 (0.92%)

WORK

Slack Technologies

$34.84

0.06 (0.17%)

TWLO

Twilio

$147.01

1.655 (1.14%)

VG

Vonage

$12.82

0.03 (0.23%)

ZM

Zoom Video

$98.50

-1.26 (-1.26%)

GOOG

Alphabet

$1,150.69

0.3 (0.03%)

MSFT

Microsoft

$138.20

-0.74 (-0.53%)

AMZN

Amazon.com

$2,019.00

-2 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 18

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 27

    Oct

  • 13

    Nov

UBER

Uber

$44.49

-0.02 (-0.04%)

, LYFT

Lyft

$64.80

(0.00%)

10:22
07/16/19
07/16
10:22
07/16/19
10:22
Periodicals
Court says NYC can ban ads inside Uber, Lyft vehicles, Reuters reports »

Reversing a lower court…

UBER

Uber

$44.49

-0.02 (-0.04%)

LYFT

Lyft

$64.80

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

FCAU

Fiat Chrysler

$13.61

-0.565 (-3.99%)

, WORK

Slack Technologies

$34.75

-0.03 (-0.09%)

10:20
07/16/19
07/16
10:20
07/16/19
10:20
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

FCAU

Fiat Chrysler

$13.61

-0.565 (-3.99%)

WORK

Slack Technologies

$34.75

-0.03 (-0.09%)

BTE

Baytex Energy

$1.47

0.03 (2.08%)

TOWN

TowneBank

$26.85

(0.00%)

VET

Vermilion Energy

$21.76

-0.2 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 29

    Jul

  • 31

    Jul

  • 11

    Sep

HD

Home Depot

$218.16

-0.55 (-0.25%)

, SON

Sonoco

$64.48

-0.005 (-0.01%)

10:20
07/16/19
07/16
10:20
07/16/19
10:20
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

HD

Home Depot

$218.16

-0.55 (-0.25%)

SON

Sonoco

$64.48

-0.005 (-0.01%)

PH

Parker-Hannifin

$172.01

4.33 (2.58%)

FDS

FactSet

$281.22

-13.02 (-4.43%)

KMT

Kennametal

$35.09

0.295 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 18

    Jul

  • 01

    Aug

  • 06

    Aug

  • 12

    Aug

  • 20

    Aug

  • 20

    Aug

  • 17

    Oct

LH

LabCorp

$174.70

0.155 (0.09%)

, TKR

Timken

$48.61

0.92 (1.93%)

10:20
07/16/19
07/16
10:20
07/16/19
10:20
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

LH

LabCorp

$174.70

0.155 (0.09%)

TKR

Timken

$48.61

0.92 (1.93%)

FCX

Freeport McMoRan

$11.23

0.09 (0.81%)

WPM

Wheaton Precious Metals

$24.45

0.27 (1.12%)

OMF

OneMain Holdings

$35.07

1.135 (3.34%)

NOK

Nokia

$5.15

0.045 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 06

    Aug

  • 09

    Aug

  • 09

    Sep

10:20
07/16/19
07/16
10:20
07/16/19
10:20
General news
The June U.S. industrial production report tracked estimates »

The June U.S. industrial…

10:20
07/16/19
07/16
10:20
07/16/19
10:20
General news
The May U.S. business inventory report tracked estimates »

The May U.S. business…

RTN

Raytheon

$178.96

0.88 (0.49%)

10:19
07/16/19
07/16
10:19
07/16/19
10:19
Hot Stocks
Raytheon submits Lower Tier Air and Missile Defense Sensor proposal to U.S. Army »

Raytheon Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
07/16/19
07/16
10:17
07/16/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
07/16/19
07/16
10:16
07/16/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$26.70

(0.00%)

10:15
07/16/19
07/16
10:15
07/16/19
10:15
Periodicals
L Brands CEO says not aware of Jeffrey Epstein's behavior, WSJ reports »

In a memo to employees on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

IQ

iQIYI

$18.97

-0.52 (-2.67%)

10:15
07/16/19
07/16
10:15
07/16/19
10:15
Options
iQiyi put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVLO

Evelo Biosciences

$7.66

(0.00%)

10:13
07/16/19
07/16
10:13
07/16/19
10:13
Hot Stocks
Breaking Hot Stocks news story on Evelo Biosciences »

Evelo Biosciences Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

10:10
07/16/19
07/16
10:10
07/16/19
10:10
General news
U.S. July NAHB housing market index rebounded 1 point to 65 »

U.S. July NAHB housing…

10:10
07/16/19
07/16
10:10
07/16/19
10:10
General news
U.S. business inventories rose 0.3% in May with sales up 0.2% »

U.S. business inventories…

EVLO

Evelo Biosciences

$7.66

(0.00%)

10:08
07/16/19
07/16
10:08
07/16/19
10:08
Hot Stocks
Breaking Hot Stocks news story on Evelo Biosciences »

Evelo Biosciences Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

SPAR

Spartan Motors

$11.40

1.49 (15.04%)

, AMZN

Amazon.com

$2,023.41

2.41 (0.12%)

10:06
07/16/19
07/16
10:06
07/16/19
10:06
Recommendations
Craig-Hallum says Spartan order is from Amazon, boosts price target to $15 »

Craig-Hallum analyst…

SPAR

Spartan Motors

$11.40

1.49 (15.04%)

AMZN

Amazon.com

$2,023.41

2.41 (0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 25

    Jul

  • 06

    Aug

DISCA

Discovery

$32.33

-0.04 (-0.12%)

10:05
07/16/19
07/16
10:05
07/16/19
10:05
Options
Discovery call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

LAD

Lithia Motors

$118.88

-0.55 (-0.46%)

10:04
07/16/19
07/16
10:04
07/16/19
10:04
Hot Stocks
Lithia Motors appoints Tina Miller as SVP, CFO »

Lithia Motors announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 13

    Nov

ALLK

Allakos

$35.10

-0.89 (-2.47%)

10:03
07/16/19
07/16
10:03
07/16/19
10:03
Hot Stocks
Allakos treatment of mastocytosis granted FDA orphan designation »

Allakos was granted FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:02
07/16/19
07/16
10:02
07/16/19
10:02
General news
Housing Market Index data reported »

July Housing Market Index…

10:02
07/16/19
07/16
10:02
07/16/19
10:02
General news
Business Inventories data reported »

May Business Inventories…

GS

Goldman Sachs

$216.98

5.43 (2.57%)

10:01
07/16/19
07/16
10:01
07/16/19
10:01
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs »

Goldman Sachs says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

DIS

Disney

$144.63

-0.42 (-0.29%)

10:00
07/16/19
07/16
10:00
07/16/19
10:00
Periodicals
ESPN to launch daily morning podcast in October, Washington Post reports »

ESPN is planning to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

COE

China Online Education

$6.84

(0.00%)

10:00
07/16/19
07/16
10:00
07/16/19
10:00
Hot Stocks
China Online Education falls -7.4% »

China Online Education is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.